Skip to main content
Erschienen in: EJNMMI Research 1/2021

Open Access 01.12.2021 | Original research

Correlation of [18F]florbetaben textural features and age of onset of Alzheimer’s disease: a principal components analysis approach

verfasst von: Jing Li, Emanuele Antonecchia, Marco Camerlenghi, Agostino Chiaravalloti, Qian Chu, Alfonso Di Costanzo, Zhen Li, Lin Wan, Xiangsong Zhang, Nicola D’Ascenzo, Orazio Schillaci, Qingguo Xie

Erschienen in: EJNMMI Research | Ausgabe 1/2021

Abstract

Background

When Alzheimer’s disease (AD) is occurring at an early onset before 65 years old, its clinical course is generally more aggressive than in the case of a late onset. We aim at identifying [\(^{18}\)F]florbetaben PET biomarkers sensitive to differences between early-onset Alzheimer’s disease (EOAD) and late-onset Alzheimer’s disease (LOAD). We conducted [\(^{18}\)F]florbetaben PET/CT scans of 43 newly diagnosed AD subjects. We calculated 93 textural parameters for each of the 83 Hammers areas. We identified 41 independent principal components for each brain region, and we studied their Spearman correlation with the age of AD onset, by taking into account multiple comparison corrections. Finally, we calculated the probability that EOAD and LOAD patients have different amyloid-\(\beta\) (\(A\beta\)) deposition by comparing the mean and the variance of the significant principal components obtained in the two groups with a 2-tailed Student’s t-test.

Results

We found that four principal components exhibit a significant correlation at a 95% confidence level with the age of onset in the left lateral part of the anterior temporal lobe, the right anterior orbital gyrus of the frontal lobe, the right lateral orbital gyrus of the frontal lobe and the left anterior part of the superior temporal gyrus. The data are consistent with the hypothesis that EOAD patients have a significantly different [\(^{18}\)F]florbetaben uptake than LOAD patients in those four brain regions.

Conclusions

Early-onset AD implies a very irregular pattern of \(A\beta\) deposition. The authors suggest that the identified textural features can be used as quantitative biomarkers for the diagnosis and characterization of EOAD patients.
Hinweise

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
AD
Alzheimer’s disease
\(A\beta\)
Amyloid-\(\beta\)
DICOM
Digital imaging and communications in medicine
EOAD
Early-onset AD
FBB
[\(^{18}\)F]florbetaben
2-[\(^{18}\)F]FDG
2-deoxy-2-[\(^{18}\)F]fluoro-d-glucose
GLCM
Gray-level co-occurrence matrix
GLDM
Gray-level dependence matrix
GLRLM
Gray-level run length matrix
GLSZM
Gray-level size zone matrix
HC
Healthy control
CG
Control group subjects
ICBM
International Consortium for Brain Mapping
LOAD
Late-onset AD
MCI
Mental cognitive impairment
MMSE
Mini-mental state examination
MRI
Magnetic resonance imaging
NGTDM
Neighborhood gray tone difference matrix
NIFTI
Neuroimaging informatics technology initiative
PCA
Principal components analysis
PET
Positron emission tomography
SPM
Statistical parametric mapping
SUV
Standardized uptake value
SUVR
Standard uptake value ratio
VOIs
Volume of interests

Background

Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by a progressive cognitive decline and dementia [1, 2]. The occurrence rate of such a diagnostic scenario is approximately doubling every 5 years after the age of 65 years old. Such a state, which represents the majority of patients, is called late-onset AD (LOAD). However, in the case of an early onset of the AD before an age of 65 years old (EOAD), the clinical course is more aggressive than in LOAD patients [39]. Clinical features of AD are characterized by the impairment of cognitive functions leading to a progressive loss of the autonomy of patients, especially in the daily activities [10]. The correct identification of the disease is crucial to distinguish AD from other types of dementia and to use the correct therapeutic approach [11, 12]. In the last decade, the role of amyloid \(\beta\)(\(A\beta\))- and tau-mediated pathology in the development of the disease has been stressed. Currently, the most promising approaches involve, on the one hand, the detection of soluble biomarkers in the cerebrospinal fluid and, on the other hand, the molecular imaging of glucose metabolism, \(A\beta\) and tau accumulation in the brain cortex with positron emission tomography (PET). Glucose metabolism shows typical alterations in AD, which are significantly related to the accumulation of tau and \(A\beta\) [13, 14]. However, EOAD introduces an additional element of complication in the AD landscape. While differences in cerebral metabolic impairment between EAOD and LOAD were observed and also supported by histopathological findings [15, 16], suggesting the existence of biological subtypes of AD, the \(A\beta\) deposition seems not to be correlated with the age of onset of AD [17].
One possibility, which so far has been explored only theoretically, is to find heterogeneity patterns of the \(A\beta\) deposition, which may significantly depend on the age of the AD onset. Textural analysis is an emerging technique for the quantitative study of tracer uptake in different regions of the brain. For example, in neuropsychiatric disorders, textural differences were found between the autism spectrum disorder and control groups in the right hippocampus, left choroid-plexus, corpus callosum and cerebellar white matter [18]. Another recent study indicated that cerebral morphometric alterations allow discrimination between the patients with attention deficit hyperactivity disorder and control subjects [19]. As the three-dimensional radiomic features quantify localized heterogeneities in brain morphology and functionality, they can be associated with neurodegenerative phenomena. By way of example, corpus callosum textures were considered as magnetic resonance imaging (MRI)-based biomarkers of AD [20]. Recently, it has been found that textural features have a distinct ability to classify AD versus healthy control (HC), mild cognitive impairment (MCI) versus HC, and AD versus MCI with maximum average accuracies of 91.5%, 83.1%, and 85.9%, respectively [21]. On this basis, biomarkers have been identified in 2-deoxy-2-[\(^{18}\)F]fluoro-d-glucose (2-[\(^{18}\)F]FDG) PET by distinguishing AD from MCI in brain regions mainly distributed in the temporal, occipital and frontal areas [22]. However, textural-based analysis of the \(A\beta\) deposition for the classification of EOAD and LOAD has not been reported yet.
It cannot be expected that the difference of the \(A\beta\) deposition between EOAD and LOAD can be identified in the entire cortex. In fact, it was observed that EOAD patients exhibit a higher degree of cortical atrophy and reduced perfusion and metabolism in parietal and lateral temporal cortices with respect to LOAD patients [14, 23, 24]. Although no evidence regarding the \(A\beta\) deposition has been found in these regions [17], it has been not considered until now that the heterogeneity of the accumulation of plaques may present also signs of the structural decline of AD brain and may differ between EOAD and LOAD patients. As a result, a reliable textural indicator of EOAD is currently missing and a texture-based analysis of the difference between EOAD and LOAD patients is not reported in the literature.
In this paper, we study 93 textural features defining the patterns of the \(A\beta\) deposition extracted from [\(^{18}\)F]florbetaben PET in 83 Hammers [25] regions covering the entire brain. By analyzing the correlations between the principal components extracted from each brain region and the age of onset of AD in a sample of 43 patients with AD diagnosis, we aim at identifying the brain areas that can express significant differences in the \(A\beta\) deposition between EOAD and LOAD subjects. We anticipate our essay to be a starting point in the investigation of the use of textural parameters extracted in [\(^{18}\)F]florbetaben PET as potential biomarkers for early diagnosis of EOAD patients, thus going beyond the traditional concepts of quantitative PET for the study of neurodegenerations.

Methods

Patient selection

All subjects gave their informed consent. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of the Policlinic Tor Vergata (Project identification code 158/16).
We enrolled 43 newly diagnosed AD patients according to the NIA-AA criteria. All AD patients were found positive to \(A\beta\) deposition. Moreover, 27 control group subjects (CG) were recruited among a group of patients with subjective cognitive decline. They did not show subsequent progression to mild cognitive impairment at follow-up (average 24 months) and were considered as the control group. All the control subjects were found negative to \(A\beta\) deposition. Doubtful cases at the visual examination were further checked by an experienced nuclear medicine physician (A.C.) by means of semi-quantitative analysis. We excluded subjects corresponding to the following criteria:
1.
Subjects with the isolated deficit and/or unmodified mini-mental state examination (MMSE) during revisits, with a Hachinski scale and radiological evidence of sub-cortical lesions;
 
2.
Presence of neurological symptoms as dysfunction of the hypothalamus and/or appendices suprasphenoidalis disease;
 
3.
Presence of pyramidal and/or extrapyramidal signs at the neurological examination;
 
4.
Presence of chronic illnesses: thyroid disease, diabetes, HIV, cancer, or previous brain injury.
 
We report the basic information of the complete dataset in Table 1.
Table 1
Overview of the subjects included in the study
 
EOAD
LOAD
Control (age \(<65\))
Control (age \(\geq65\))
[\(n=14\)]
[\(n=29\)]
[\(n=9\)]
[\(n=18\)]
Age (mean ± SD)
\(58.93\pm 3.00\)
\(70.76\pm 4.28\)
\(60.89\pm 2.62\)
\(72.28\pm 3.71\)
Gender (Woman; Man)
10 W; 4 M
16 W; 13 M
7 W; 2 M
13 W; 5 M
MMSE (mean ± SD)
\(15.77\pm 6.56\)
\(18.82\pm 5.45\)

Scanning protocol

We conducted PET/CT scans in the Nuclear Medicine Facility of the Policlinic Tor Vergata, Rome, Italy. The Siemens Biograph PET/CT system at Tor Vergata was used to assess [\(^{18}\)F]florbetaben uptake.
All the subjects were injected intravenously with 295–320 MBq [\(^{18}\)F]florbetaben and hydrated with 500 ml of saline (0.9% sodium chloride). PET/CT scan was started approximately 90 min after [\(^{18}\)F]florbetaben injection. To avoid movement artifacts, four stacks of dynamic images (4 frames of 300 s each) were acquired in a 3D-mode standard technique.
The voxel size of PET image was \(2.0\times 2.0\times 2.0\) mm\(^3\). PET image reconstruction was performed using the three-dimensional ordered-subsets expectation maximization (OSEM) method with 4 subsets and 14 iterations.

Image processing

We performed the PET image registration and normalization steps by using statistical parametric mapping (SPM12). We first converted each individual [\(^{18}\)F]florbetaben PET brain DICOM image to Neuroimaging Informatics Technology Initiative (NIFTI) data. We then normalized the obtained NIFTI images to the standard International Consortium for Brain Mapping (ICBM) template using the mutual information affine registration (standard space composed of \(91\times 109\times 91\) voxels with a resolution of \(2\times 2\times 2\) mm\(^3\)) as in Fig. 1a. We resliced the Hammers N30R83 Atlas [25, 26] to the standard ICBM template using the mutual information affine registration with a resolution of \(2\times 2\times 2\) mm\(^3\) as reported in Fig. 1b. We identified each of the 83 Hammers areas as volume of interests (VOIs) with a point multiplication between the masks and the normalized PET images. For instance, we report the example of the superior temporal gyrus and the parietal gyrus in Fig. 1c, d, respectively.
We represented the Standardized Uptake Value (SUV) in each region using 256 gray levels. We further considered a rebinning with bin width \(W=1,2,8,16,32,64,128\). For each VOI and each bin width, we calculated 93 textural features by using the software framework pyradiomics (v3.0.1) [27]. The textural parameters are extracted from six classes of matrices. The gray-level co-occurrence matrix (GLCM) quantifies the frequency of co-occurrence of a certain gray level within 26-connected neighbors of each pixel of the PET image [28, 29]. The gray-level dependence matrix (GLDM) quantifies gray-level dependencies in an image, and these gray-level dependencies quantify the distribution frequency of the 26-connected neighbors dependent on the center voxels [30]. To quantify the spatial distribution of adjacent gray levels, the gray-level run length matrix (GLRLM) textural features are used to represent the number of runs of a given length for each gray level [29, 31]. To identify structures with a certain tracer uptake, the gray-level size zone matrix (GLSZM) is used to classify the size of 3D volume with a given gray level [29]. Finally, in order to identify proper border features in a certain brain region, the neighborhood gray-tone difference matrix (NGTDM) is used to represent the sum of the gray-level differences between each pixel and the 26-connected neighbors [29, 32]. We report the list of studied parameters in Table 2.
Table 2
Textural parameters used in the analysis
Type
ID
Name
Width
GLDM
1
Dependence entropy
64
2
Dependence non uniformity
64
3
Dependence non uniformity normalized
64
4
Dependence variance
64
5
Gray level non uniformity
64
6
Gray level variance
64
7
High gray level emphasis
32
8
Large dependence emphasis
64
9
Large dependence high gray level emphasis
32
10
Large dependence low gray level emphasis
32
11
Low gray level emphasis
64
12
Small dependence emphasis
1
13
Small dependence high gray level emphasis
64
14
Small dependence low gray level emphasis
64
GLSZM
15
Gray level non uniformity
1
16
Gray level non uniformity normalized
64
17
Gray level variance
64
18
High gray level zone emphasis
64
19
Large area emphasis
1
20
Large area high gray level emphasis
8
21
Large area low gray level emphasis
2
22
Low gray level zone emphasis
64
23
Size zone non uniformity
1
24
Size zone non uniformity normalized
1
25
Small area emphasis
1
26
Small area high gray level emphasis
64
27
Small area low gray level emphasis
8
28
Zone entropy
2
29
Zone percentage
1
30
Zone variance
64
GLCM
31
Autocorrelation
32
32
Cluster prominence
128
33
Cluster shade
128
34
Cluster tendency
64
35
Contrast
128
36
Correlation
64
37
Difference average
64
38
Difference entropy
64
39
Difference variance
128
40
Id
64
41
Idm
64
42
Idmn
64
43
Idn
64
44
Imc1
8
45
Imc2
64
46
Inverse variance
64
47
Joint average
32
48
Joint energy
64
49
Joint entropy
64
50
MCC
64
51
Maximum probability
32
52
Sum average
32
53
Sum entropy
64
54
Sum squares
64
NGTDM
55
Busyness
64
56
Coarseness
64
57
Complexity
128
58
Contrast
8
59
Strength
64
GLRLM
60
Gray level non uniformity
64
61
Gray level non unifromity normalized
64
62
Gray level variance
64
63
High gray level run emphasis
32
64
Long run emphasis
64
65
Long run high gray level emphasis
64
66
Long run low gray level emphasis
32
67
Low gray level run emphasis
64
68
Run entropy
64
69
Run length non uniformity
64
70
Run length non uniformity normalized
64
71
Run percentage
64
72
Run variance
64
73
Short run emphasis
64
74
Short run high gray level emphasis
64
75
Short run low gray level emphasis
32
First order
76
10 Percentile
1
77
90 Percentile
1
78
Energy
1
79
Entropy
1
80
Entropy
1
81
Kurtosis
1
82
Mean absolute deviation
1
83
Mean
1
84
Median
1
85
Robust mean absolute deviation
1
86
Root mean squared
1
87
Skewness
1
88
Total energy
1
89
Uniformity
64
90
Variance
1
91
Maximum
1
92
Minimum
1
93
Range
1
The last column reports the optimal bin width used for the estimate of each parameter
Although control subjects were found negative to \(A\beta\) deposition, the background tracer perfusion is visible in the PET images. Therefore, the textural analysis of the [\(^{18}\)F]florbetaben PET of the control group provides a measurement of the textural parameters level of the background.

Statistical analysis

The first step of the statistical analysis consisted of selecting the proper bin width for each textural parameter. To this aim, we calculated the correlation of the textural parameters and the age of onset in the AD patients group for each bin width by using a Spearman correlation statistical test. We selected the optimal bin width for which the Spearman correlation coefficient was maximal. At this stage, we remained 7719 parameters describing the textural properties of the [\(^{18}\)F]florbetaben uptake distribution in the brain, namely 93 textural features for each of the 83 Hammers regions.
The second step of the statistical analysis consisted of applying a features reduction strategy based on the principal components analysis (PCA). We identified in each brain region r the number \(N_{{\rm ind}}^r\) of independent principal components \(f_i^r\) accounting for 90% of the total variance [33, 34]. We restricted the further analysis to these independent principal components \(f_i^r\). We studied the correlation between \(f_i^r\) and the age of AD onset using the Spearman correlation statistical method, by selecting only those significant principal components \(f_i^r\) exhibiting a correlation coefficient \(|r|>0.5\) (\(P<0.05/N_{{\rm ind}}^r\)). We applied a Bonferroni correction taking into account the multiple comparisons between independent statistical tests within each brain region [3538].
The third step of the statistical analysis consisted of identifying the age range at which EOAD and LOAD exhibit significant differences. To this aim, we considered the null hypothesis that EOAD and LOAD do not differ, where EOAD and LOAD were defined with respect to a variable threshold age of onset \({\mathcal{A}}\). We divided the patients into two groups, with the age of onset higher and lower than \({\mathcal{A}}\). Within each group, we calculated the average \(\mu _{i}\) and the variance \(\sigma _{i}\) of each of the significant principal components \(f_i^r\). The \({\mathcal{A}}\) was spanned from 55 to 75 years. For each \({\mathcal{A}}\) and for each selected principal component, we calculated the probability that the null hypothesis was satisfied with a 2-tailed Student’s t-test by comparing the mean \(\mu _{i}\) and the variance \(\sigma _i\) in the two groups. We indicated the P-value obtained with [\(^{18}\)F]florbetaben PET imaging for each \({\mathcal{A}}\) as \(P_{{\rm FBB}}\left( {\mathcal{A}}\right)\). We considered a P-value \(P_{{\rm FBB}}\left( {\mathcal{A}}\right) _{{\rm sig}} = 0.05/N_{{\rm ind}}^r\) as expressing a 95% confidence level on the rejection of the null hypothesis, by including the multiple comparisons correction. Finally, we considered the range of threshold age of onset \({\mathcal{A}}\) of which the P-value was lower than \(P_{{\rm FBB}}\left( {\mathcal{A}}\right) _{{\rm sig}}\) as the range of age of onsets for which EOAD and LOAD are significantly different at a 95% confidence level.

Results

Correlation of [\(^{18}\)F]florbetaben SUV and AD age of onset

The SUV of [\(^{18}\)F]florbetaben uptake in the different Hammers brain areas of patients with AD diagnosis does not exhibit a dependence on the age of onset of the disease. As an example, we report the maximal projection [\(^{18}\)F]florbetaben PET image of the right lateral orbital gyrus of the frontal lobe for an EOAD and a LOAD patient in Fig. 2. As we observe in the figure, the average [\(^{18}\)F]florbetaben PET uptake does not significantly differ from EOAD and LOAD patients. To support this qualitative statement, we studied the dependence of the average [\(^{18}\)F]florbetaben PET uptake versus AD age of onset for the entire cohort of patients. We report the example of the left lateral part of the anterior temporal lobe, the right anterior orbital gyrus of the frontal lobe, the right lateral orbital gyrus of the frontal lobe and the left anterior part of the superior temporal gyrus in Fig. 3. We did not find any significant correlation between the average SUV and the age of onset of AD. We confirmed the absence of the correlation of average [\(^{18}\)F]florbetaben PET SUV in all the Hammers regions. Similarly, the Standard Uptake Value Ratio (SUVR) calculated by normalizing the value of the SUV to the background estimated in the amygdala did not exhibit any correlation with the age of onset.

Correlation of textural features and AD age of onset

Despite the absence of a direct correlation of average [\(^{18}\)F]florbetaben PET uptake and age of onset of AD, a careful analysis of the 83 Hammers regions allows identifying heterogeneous structures and aggregates. This observation was at the basis of a quantitative characterization of these structures by means of textural features. We report the optimal bin width used for the estimation of the 93 textural parameters in each of the 83 Hammers regions in Table 2.
The textural parameters considered in this study are intimately correlated within each brain region, due to the fact that they are calculated on the basis of a finite set of six textural matrices. We performed a principal components analysis of the textural features in each brain region. We report the number of independent principal components accounting for 90% of the total variance in each region in Table 3.
Table 3
Brain regions and number of principal components
Region
ID
\({N_{{\rm ind}}^r}\)
Frontal lobe
Middle frontal gyrus
28, 29
6, 5
Precentral gyrus
50, 51
6, 7
Straight gyrus
52, 53
6, 6
Anterior orbital gyrus
54, 55
7, 6
Inferior frontal gyrus
56, 57
6, 7
Superior frontal gyrus
58, 59
6, 7
Medial orbital gyrus
68, 69
8, 4
Lateral orbital gyrus
70, 71
6, 5
Posterior orbital gyrus
72, 73
6, 6
Subgenual frontal cortex
76, 77
7, 7
Subcallosal area
78, 79
8, 8
Pre-subgenual frontal cortex
80, 81
6, 7
Temporal lobe
Hippocampus
2, 1
8, 7
Amygdala
4, 3
7, 8
Anterior temporal lobe medial part
6, 5
7, 7
Anterior temporal lobe lateral part
8, 7
6, 5
Parahippocampal and ambient gyri
10, 9
7, 8
Superior temporal gyrus posterior part
12, 11
5, 7
Middle and interior temporal gyrus
14, 13
6, 6
Fusiform gyrus
16, 15
6, 8
Posterior temporal lobe
30, 31
5, 7
Superior temporal gyrus anterior part
82, 83
7, 8
Parietal lobe
Parietal gyrus
60, 61
7, 7
Superior parietal gyrus
62, 63
6, 8
Inferolateral remainder of parietal lobe
32, 33
6, 5
Occipital lobe
Lateral remainder of occipital lobe
22, 23
6, 6
Lingua gyrus
64, 65
7, 6
Cuneus
66, 67
8, 8
Central structure
Caudate nucleus
34, 35
8, 8
Nucleus accumbens
36, 37
8, 8
Putamen
38, 39
6, 8
Thalamus
40, 41
7, 7
Pallidum
42, 43
7, 6
Substantia nigra
74, 75
8, 7
Corpus Callosum
44
6
Insula and cingulate gyri
Insula
20, 21
5, 6
Cingulate gyrus anterior part
24, 25
7, 9
Cingulate gyrus posterior part
26, 27
8, 7
Posterior fossa
Cerebellum
18, 17
4, 5
Brainstem
19
5
Ventricles
Lateral ventricle
46, 45
8, 8
Lateral ventricle temporal horn
48, 47
10, 5
Third ventricle
49
9
We found that four principal components exhibit a strong correlation with the age of onset of AD in the temporal lobe (Fig. 4a, b) and in the frontal lobe (Fig. 5a, b), respectively. The component \(f_{0}\) in the left lateral part of the anterior temporal lobe accounts for 43.7% of the total variance and exhibits a significant correlation with the age of onset of AD (r = − 0.55, p = \(1.3\times 10^{-4}\)). The background estimated using control subject data does not exhibit any significant correlation. Similarly, the component \(f_0\) in the right anterior orbital gyrus of the frontal lobe accounts for 47.2% of the total variance and exhibits a significant correlation with the age of onset of AD (r = − 0.52, p = \(3.7\times 10^{-4}\)). The component \(f_0\) in the right lateral orbital gyrus of the frontal lobe accounts for 50.8% of the total variance and exhibits a significant correlation with the age of onset of AD (r = − 0.51, r = \(4.3\times 10^{-4}\)). The component \(f_1\) in the left anterior part of the superior temporal gyrus accounts for 21.0% of the total variance and exhibits a significant correlation with the age of onset of AD (r = − 0.49, r = \(8.4\times 10^{-4}\)). We report the main features contributing to the linear expansion of the four principal components in Table 4. They are identified as the ones with coefficients \(\left| c_j\right| > 0.9\times \max \left| c_i\right|\).
Table 4
Selected principal components and most significant textural features
Principal component
Region
Textural features
\(f_0\)
Left lateral part of the anterior temporal lobe (8)
1, 2, 3, 5, 6, 8, 32, 34, 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 48, 49, 53, 54, 57, 58, 60, 61, 63, 64, 69, 70, 71, 79, 92
\(f_0\)
Right anterior orbital gyrus of the frontal lobe (55)
1, 5, 6, 12, 16, 29, 30, 34, 49, 53, 54, 56, 60, 61, 79, 80, 83, 88, 92
\(f_0\)
Right lateral orbital gyrus of the frontal lobe (71)
2, 3, 5, 6, 8, 32, 35, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 48, 49, 53, 54, 60, 61, 62, 64, 68, 69, 70, 71, 79, 83, 92, 93
\(f_1\)
Left anterior part of the superior temporal gyrus (82)
7, 9, 11, 31, 47, 52, 63, 65, 67, 76, 78, 84, 85, 86, 89, 91

Difference between EOAD and LOAD

The correlation of the four principal components identified above and the age of onset of AD can be used to clarify the threshold age \({\mathcal{A}}\), at which the group of EOAD and LOAD patients is significantly different. In order to provide a graphical representation of this concept, we show the candle plot of the value of the significant components for AD and control subjects with a threshold age \({\mathcal{A}}=65\) years in Fig. 6. We observe that the value of the textural parameters in EOAD patients differs of approximately 20% between EOAD, LOAD and background uptake estimated from control subjects.
For a more quantitative estimation of the level of significance, we report in Figs. 4c, d and 5c, d the P-value of the Student’s t-test applied to the distribution of the four principal components in the left lateral part of the anterior temporal lobe, the right anterior orbital gyrus of the frontal lobe, the right lateral orbital gyrus of the frontal lobe and the left anterior part of the superior temporal gyrus corresponding to EOAD and LOAD patients defined with an age of onset threshold \({\mathcal{A}}\). Parameter ranges can be identified for those principal components, in which a 95% confidence level significance is reached, corresponding to the age range for which \(P<0.05/N_{{\rm ind}}^r\). In particular, the four identified principal components exhibit a significant difference between the EOAD and LOAD groups, when the threshold age is set at 65 years.

Discussion

The findings presented above need to be discussed from the perspective of both medical physics and clinical significance. The key advantage of the textural analysis approach used in this paper is the possibility to identify a clear signature of EOAD patients. We studied the \(A\beta\) deposition measured with [\(^{18}\)F]florbetaben PET in 83 Hammers brain regions, and despite the absence of a significant correlation of any first-order statistical characteristics of the SUV distribution and age of onset of AD, we found four independent principal components in the left lateral part of the anterior temporal lobe, the right anterior orbital gyrus of the frontal lobe, the right lateral orbital gyrus of the frontal lobe and the left anterior part of the superior temporal gyrus exhibiting a significant correlation with the age of onset of AD.
The features generating the principal components reflect the degree of association between different voxels in the same brain region [32]. By way of example, the GLDM describes the gray-level dependencies in an image. A higher value of the textural features extracted from GLDM implies a larger number of areas with different sizes and different values. In other words, a larger value of a textural feature extracted from GLDM corresponds to a heterogeneous and irregular spatial distribution, with a series of complex correlation structures between the voxels. The textural analysis proposed in this paper suggests in particular that the \(A\beta\) deposition in the left lateral part of the anterior temporal lobe, the right anterior orbital gyrus of the frontal lobe, the right lateral orbital gyrus of the frontal lobe and the left anterior part of the superior temporal gyrus follows a significantly more complex pattern in correspondence to an early age of onset of AD.
The use of the textural features for the verification of the presence of intrinsic structures and patterns finds agreement in other studies [22]. In particular, textural features extracted from GLDM were relevant to cognitive scale values and correlated with the insurgence of AD and MCI, suggesting that 2-[\(^{18}\)F]FDG brain PET imaging not only can be used for classification diagnosis but also contain information related to the pathological process [3942]. Abnormalities of the pattern of \(A\beta\) deposition were also observed in connection to AD. Textural features extracted from the GLRLM in the fused [\(^{18}\)F]florbetaben PET/MRI images were also used recently to understand cognitive and behavioral issues in patients with AD [22]. Textural features of MRI images were also used for the identification of structural and morphological alterations occurring in the hippocampus and in the corpus callosum of AD and MCI subjects, as well as of patients with autism spectrum and hyperactivity disorder [20, 21, 4345]. A limitation of previous studies, as noticed also in [22], is the absence of an age-dependent classification. Our study is thus showing that such pre-classification is not only needed, but also reveals a fundamental difference between patients with an early and a late diagnosis of AD. The analysis of \(A\beta\) deposition data represents also a unique point of innovation of this paper with respect to previous findings.
Our observation is consistent with most findings reported in the literature for the characterization of AD patients [19, 4650]. More interestingly, our findings stress the evidence of differences between EOAD and LOAD, thus indicating a possible intrinsic pathological ground. The statistical methods applied in this study in fact justify a difference of the distribution pattern of the \(A\beta\) deposition in the left lateral part of the anterior temporal lobe, the right anterior orbital gyrus of the frontal lobe, the right lateral orbital gyrus of the frontal lobe and the left anterior part of the superior temporal gyrus. In this paper, we developed a prognostic model, schematically represented in Fig. 7, which is ready to be externally validated on independent datasets and independent clinical trials [51]. However, more gender-differentiated data would be needed to understand whether epidemiological factors play a role in this analysis. Moreover, larger statistics may enhance the significance of the brain regions that, although exhibiting an age-dependent behavior, do not disentangle EOAD and LOAD patients.
In a recently published study, we reported that the increased \(A\beta\) deposition alone cannot explain the clinical differences between EOAD and LOAD patients [17]. The results presented here are not in contradiction with previous findings. While in [17] we made the observations only based on the SUV, here we extended the analysis to the recognition and possible interpretation of patterns. Different metabolic patterns between EOAD and LOAD were identified in the left parietal lobe and in inferior brain regions by using 2-[\(^{18}\)F]FDG PET [52, 53], contributing to the hypothesis that the regional vulnerability of associative areas of the brain represents a possible signature of EOAD. Moreover, extrapyramidal symptoms and frontal dysfunction are more common in EOAD than in LOAD patients [53], therefore supporting our observations in the left lateral part of the anterior temporal lobe, the right anterior orbital gyrus of the frontal lobe, the right lateral orbital gyrus of the frontal lobe and the left anterior part of the superior temporal gyrus. The role of \(A\beta\) in this scenario, however, is still unclear. Our findings enhanced the potential association of a highly fragmented \(A\beta\) distribution with the age of onset of AD. This observation allows a large number of possible explanations. For example, as already suggested in [17], the increased textural disorder observed in the \(A\beta\) deposition and glucose metabolism may be in fact related to the inability to reduce highly toxic soluble \(A\beta\) oligomers into relatively less toxic insoluble plaques.

Conclusions

We have found that four principal components exhibit a significant correlation at a 95% confidence level with the age of onset in the left lateral part of the anterior temporal lobe, the right anterior orbital gyrus of the frontal lobe, the right lateral orbital gyrus of the frontal lobe and the left anterior part of the superior temporal gyrus. Data are consistent with the hypothesis that AD patients with age of onset at the age younger than 65 years exhibit significant difference with respect to patients with later onset at 95% confidence level in the spatial patterns of the \(A\beta\) deposition in the left lateral part of the anterior temporal lobe, the right anterior orbital gyrus of the frontal lobe, the right lateral orbital gyrus of the frontal lobe and the left anterior part of the superior temporal gyrus.
Our findings support the textural analysis approach to the investigation of the AD pathology, intending to define novel biomarkers for a faster clinical diagnosis of EOAD. The textural parameters identified in this paper are the basis of further experiments in order to investigate the biological and functional interpretation of the mechanism on the basis of this typical EOAD signature.

Acknowledgements

This work was supported by National Key Research and Development Program of China (Grant No. 2019YFC0118900), by National R&D Program for Major Research Instruments of Natural Science Foundation of China (Grant No. 61927801, No. 62027808), by MAECI Great Relevance 2019 contributions Italy-China (Grant No. PGR00846) and by PICASO project Grant (Grant No. 689209).

Declarations

The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of the Policlinic Tor Vergata (Project identification code 158/16).
Not applicable.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Sperling RA, Dickerson BC, Pihlajamaki M, Vannini P, LaViolette PS, Vitolo OV, Hedden T, Becker JA, Rentz DM, Selkoe DJ, et al. Functional alterations in memory networks in early Alzheimer’s disease. Neuromol Med. 2010;12(1):27–43.CrossRef Sperling RA, Dickerson BC, Pihlajamaki M, Vannini P, LaViolette PS, Vitolo OV, Hedden T, Becker JA, Rentz DM, Selkoe DJ, et al. Functional alterations in memory networks in early Alzheimer’s disease. Neuromol Med. 2010;12(1):27–43.CrossRef
2.
Zurück zum Zitat Tapiola T, Pirttilä T, Mehta PD, Alafuzoff I, Lehtovirta M, Soininen H. Relationship between apoe genotype and csf \(\beta\)-amyloid (1–42) and tau in patients with probable and definite Alzheimer’s disease. Neurobiol Aging. 2000;21(5):735–40.PubMedCrossRef Tapiola T, Pirttilä T, Mehta PD, Alafuzoff I, Lehtovirta M, Soininen H. Relationship between apoe genotype and csf \(\beta\)-amyloid (1–42) and tau in patients with probable and definite Alzheimer’s disease. Neurobiol Aging. 2000;21(5):735–40.PubMedCrossRef
3.
Zurück zum Zitat Mercy L, Hodges J, Dawson K, Barker R, Brayne C. Incidence of early-onset dementias in Cambridgeshire, United Kingdom. Neurology. 2008;71(19):1496–9.PubMedCrossRef Mercy L, Hodges J, Dawson K, Barker R, Brayne C. Incidence of early-onset dementias in Cambridgeshire, United Kingdom. Neurology. 2008;71(19):1496–9.PubMedCrossRef
4.
Zurück zum Zitat Ratnavalli E, Brayne C, Dawson K, Hodges J. The prevalence of frontotemporal dementia. Neurology. 2002;58(11):1615–21.PubMedCrossRef Ratnavalli E, Brayne C, Dawson K, Hodges J. The prevalence of frontotemporal dementia. Neurology. 2002;58(11):1615–21.PubMedCrossRef
5.
Zurück zum Zitat Koss E, Edland S, Fillenbaum G, Mohs R, Clark C, Galasko D, Morris J. Clinical and neuropsychological differences between patients with earlier and later onset of Alzheimer’s disease: a cerad analysis, part xii. Neurology. 1996;46(1):136–41.PubMedCrossRef Koss E, Edland S, Fillenbaum G, Mohs R, Clark C, Galasko D, Morris J. Clinical and neuropsychological differences between patients with earlier and later onset of Alzheimer’s disease: a cerad analysis, part xii. Neurology. 1996;46(1):136–41.PubMedCrossRef
6.
Zurück zum Zitat Seltzer B, Sherwin I. A comparison of clinical features in early-and late-onset primary degenerative dementia: one entity or two? Arch Neurol. 1983;40(3):143–6.PubMedCrossRef Seltzer B, Sherwin I. A comparison of clinical features in early-and late-onset primary degenerative dementia: one entity or two? Arch Neurol. 1983;40(3):143–6.PubMedCrossRef
7.
Zurück zum Zitat Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351–5.PubMedCrossRef Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351–5.PubMedCrossRef
8.
Zurück zum Zitat Nordström P, Nordström A, Eriksson M, Wahlund LO, Gustafson Y. Risk factors in late adolescence for young-onset dementia in men: a nationwide cohort study. JAMA Intern Med. 2013;17:1612–22.CrossRef Nordström P, Nordström A, Eriksson M, Wahlund LO, Gustafson Y. Risk factors in late adolescence for young-onset dementia in men: a nationwide cohort study. JAMA Intern Med. 2013;17:1612–22.CrossRef
10.
Zurück zum Zitat Sacco G, Joumier V, Darmon N, Dechamps A, Derreumaux A, Lee J-H, Piano J, Bordone N, Konig A, Teboul B, David R, Guerin O, Bremond F, Robert P. Detection of activities of daily living impairment in Alzheimer’s disease and mild cognitive impairment using information and communication technology. Clin Interv Aging. 2012;7:539–49. https://doi.org/10.2147/CIA.S36297.CrossRefPubMedPubMedCentral Sacco G, Joumier V, Darmon N, Dechamps A, Derreumaux A, Lee J-H, Piano J, Bordone N, Konig A, Teboul B, David R, Guerin O, Bremond F, Robert P. Detection of activities of daily living impairment in Alzheimer’s disease and mild cognitive impairment using information and communication technology. Clin Interv Aging. 2012;7:539–49. https://​doi.​org/​10.​2147/​CIA.​S36297.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, Trojanowski JQ, Toga AW, Beckett L. Ways toward an early diagnosis in Alzheimer’s disease: the Alzheimer’s disease neuroimaging initiative (adni). Alzheimer’s Dementia J Alzheimer’s Assoc. 2005;1:55–66.CrossRef Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, Trojanowski JQ, Toga AW, Beckett L. Ways toward an early diagnosis in Alzheimer’s disease: the Alzheimer’s disease neuroimaging initiative (adni). Alzheimer’s Dementia J Alzheimer’s Assoc. 2005;1:55–66.CrossRef
12.
Zurück zum Zitat Nelson L, Tabet N. Slowing the progression of Alzheimer’s disease; what works? Ageing Res Rev. 2015;23:193–209.PubMedCrossRef Nelson L, Tabet N. Slowing the progression of Alzheimer’s disease; what works? Ageing Res Rev. 2015;23:193–209.PubMedCrossRef
13.
Zurück zum Zitat Chiaravalloti A, Barbagallo G, Ricci M. Brain metabolic correlates of csf tau protein in a large cohort of Alzheimer’s disease patients: a csf and fdg pet study. Brain Res. 2018;1678:116–22.PubMedCrossRef Chiaravalloti A, Barbagallo G, Ricci M. Brain metabolic correlates of csf tau protein in a large cohort of Alzheimer’s disease patients: a csf and fdg pet study. Brain Res. 2018;1678:116–22.PubMedCrossRef
14.
Zurück zum Zitat Lanoiselée H-M, Nicolas G, Wallon D, Rovelet-Lecrux A, Lacour M, Rousseau S, Richard A-C, Pasquier F, Rollin-Sillaire A, Martinaud O, et al. App, psen1, and psen2 mutations in early-onset Alzheimer disease: a genetic screening study of familial and sporadic cases. PLoS Med. 2017;14(3):1002270.CrossRef Lanoiselée H-M, Nicolas G, Wallon D, Rovelet-Lecrux A, Lacour M, Rousseau S, Richard A-C, Pasquier F, Rollin-Sillaire A, Martinaud O, et al. App, psen1, and psen2 mutations in early-onset Alzheimer disease: a genetic screening study of familial and sporadic cases. PLoS Med. 2017;14(3):1002270.CrossRef
15.
Zurück zum Zitat Kim E, Cho S, Jeong Y, Park K, Kang S, Kang E, Kim SE, Lee K, Na D. Glucose metabolism in early onset versus late onset Alzheimer’s disease: an spm analysis of 120 patients. Brain. 2005;128(8):1790–801.PubMedCrossRef Kim E, Cho S, Jeong Y, Park K, Kang S, Kang E, Kim SE, Lee K, Na D. Glucose metabolism in early onset versus late onset Alzheimer’s disease: an spm analysis of 120 patients. Brain. 2005;128(8):1790–801.PubMedCrossRef
16.
Zurück zum Zitat Sakamoto S, Ishii K, Sasaki M, Hosaka K, Mori T, Matsui M, Hirono N, Mori E. Differences in cerebral metabolic impairment between early and late onset types of Alzheimer’s disease. J Neurol Sci. 2002;200(1–2):27–32.PubMedCrossRef Sakamoto S, Ishii K, Sasaki M, Hosaka K, Mori T, Matsui M, Hirono N, Mori E. Differences in cerebral metabolic impairment between early and late onset types of Alzheimer’s disease. J Neurol Sci. 2002;200(1–2):27–32.PubMedCrossRef
17.
Zurück zum Zitat Chiaravalloti A, Barbagallo G, Castellano AE, Ricci M, Ciccariello G, Ursini F, D’Ascenzo N, Xie Q, Schillaci O. [18f] fbb cortical uptake is not related to the age of onset of Alzheimer’s disease. Nucl Med Commun. 2020;41:175–80.PubMedCrossRef Chiaravalloti A, Barbagallo G, Castellano AE, Ricci M, Ciccariello G, Ursini F, D’Ascenzo N, Xie Q, Schillaci O. [18f] fbb cortical uptake is not related to the age of onset of Alzheimer’s disease. Nucl Med Commun. 2020;41:175–80.PubMedCrossRef
18.
Zurück zum Zitat Chaddad A, Desrosiers C, Toews M. Multi-scale radiomic analysis of sub-cortical regions in mri related to autism, gender and age. Sci Rep. 2017;7(1):45639–45639.PubMedPubMedCentralCrossRef Chaddad A, Desrosiers C, Toews M. Multi-scale radiomic analysis of sub-cortical regions in mri related to autism, gender and age. Sci Rep. 2017;7(1):45639–45639.PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Sun H, Chen Y, Huang Q, Lui S, Huang X, Shi Y, Xu X, Sweeney JA, Gong Q. Psychoradiologic utility of mr imaging for diagnosis of attention deficit hyperactivity disorder: a radiomics analysis. Radiology. 2017;287(2):620–30.PubMedCrossRef Sun H, Chen Y, Huang Q, Lui S, Huang X, Shi Y, Xu X, Sweeney JA, Gong Q. Psychoradiologic utility of mr imaging for diagnosis of attention deficit hyperactivity disorder: a radiomics analysis. Radiology. 2017;287(2):620–30.PubMedCrossRef
20.
Zurück zum Zitat Feng Q, Chen Y, Liao Z, Jiang H, Mao D, Wang M, Yu E, Ding Z. Corpus callosum radiomics-based classification model in Alzheimer’s disease: a case-control study. Front Neurol. 2018;9:618.PubMedPubMedCentralCrossRef Feng Q, Chen Y, Liao Z, Jiang H, Mao D, Wang M, Yu E, Ding Z. Corpus callosum radiomics-based classification model in Alzheimer’s disease: a case-control study. Front Neurol. 2018;9:618.PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Feng F, Wang P, Zhao K, Zhou B, Yao H, Meng Q, Wang L, Zhang Z, Ding Y, Wang L, An N, Zhang X, Liu Y. Radiomic features of hippocampal subregions in Alzheimer’s disease and amnestic mild cognitive impairment. Front Ag Neurosci. 2018;1:290.CrossRef Feng F, Wang P, Zhao K, Zhou B, Yao H, Meng Q, Wang L, Zhang Z, Ding Y, Wang L, An N, Zhang X, Liu Y. Radiomic features of hippocampal subregions in Alzheimer’s disease and amnestic mild cognitive impairment. Front Ag Neurosci. 2018;1:290.CrossRef
22.
Zurück zum Zitat Li Y, Jiang J, Lu J, Jiang J, Zhang H, Zuo C. Radiomics: a novel feature extraction method for brain neuron degeneration disease using 18f-fdg pet imaging and its implementation for Alzheimer’s disease and mild cognitive impairment. Therap Adv Neurol Disord. 2019;12:1–21. Li Y, Jiang J, Lu J, Jiang J, Zhang H, Zuo C. Radiomics: a novel feature extraction method for brain neuron degeneration disease using 18f-fdg pet imaging and its implementation for Alzheimer’s disease and mild cognitive impairment. Therap Adv Neurol Disord. 2019;12:1–21.
23.
Zurück zum Zitat Frisoni G, Testa C, Sabattoli F, Beltramello A, Soininen H, Laakso M. Structural correlates of early and late onset Alzheimer’s disease: voxel based morphometric study. J Neurol Neurosur Psychiatry. 2005;76(1):112–4.CrossRef Frisoni G, Testa C, Sabattoli F, Beltramello A, Soininen H, Laakso M. Structural correlates of early and late onset Alzheimer’s disease: voxel based morphometric study. J Neurol Neurosur Psychiatry. 2005;76(1):112–4.CrossRef
24.
Zurück zum Zitat Karas G, Scheltens P, Rombouts S, Van Schijndel R, Klein M, Jones B, Van Der Flier W, Vrenken H, Barkhof F. Precuneus atrophy in early-onset Alzheimer’s disease: a morphometric structural mri study. Neuroradiology. 2007;49(12):967–76.PubMedCrossRef Karas G, Scheltens P, Rombouts S, Van Schijndel R, Klein M, Jones B, Van Der Flier W, Vrenken H, Barkhof F. Precuneus atrophy in early-onset Alzheimer’s disease: a morphometric structural mri study. Neuroradiology. 2007;49(12):967–76.PubMedCrossRef
25.
Zurück zum Zitat Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, Mitchell TN, Brooks DJ, Duncan JS. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19(4):224–47.PubMedPubMedCentralCrossRef Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, Mitchell TN, Brooks DJ, Duncan JS. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19(4):224–47.PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Gousias IS, Rueckert D, Heckemann RA, Dyet L, Boardman JP, Edwards AD, Hammers A. Automatic segmentation of brain mris of 2-year-olds into 83 regions of interest. NeuroImage. 2008;40(2):672–84.PubMedCrossRef Gousias IS, Rueckert D, Heckemann RA, Dyet L, Boardman JP, Edwards AD, Hammers A. Automatic segmentation of brain mris of 2-year-olds into 83 regions of interest. NeuroImage. 2008;40(2):672–84.PubMedCrossRef
27.
Zurück zum Zitat Van Griethuysen JJ, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, Beets-Tan RG, Fillion-Robin J-C, Pieper S, Aerts HJ. Computational radiomics system to decode the radiographic phenotype. Cancer Res. 2017;77(21):104–7.CrossRef Van Griethuysen JJ, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, Beets-Tan RG, Fillion-Robin J-C, Pieper S, Aerts HJ. Computational radiomics system to decode the radiographic phenotype. Cancer Res. 2017;77(21):104–7.CrossRef
30.
Zurück zum Zitat Sun C, Wee WG. Neighboring gray level dependence matrix for texture classification. Comput Vis Gr Image Process. 1983;23(3):341–52.CrossRef Sun C, Wee WG. Neighboring gray level dependence matrix for texture classification. Comput Vis Gr Image Process. 1983;23(3):341–52.CrossRef
33.
Zurück zum Zitat Gao X, Starmer J, Martin E. A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. Genet Epidemiol. 2008;32:361–9.PubMedCrossRef Gao X, Starmer J, Martin E. A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. Genet Epidemiol. 2008;32:361–9.PubMedCrossRef
34.
Zurück zum Zitat Johnson R, Nelson G, Troyer J, Lautenberger J, Kessing B, Wrinkler C, OBrien S. Accounting for multiple comparisons in a genome-wide association study (gwas). BMC Genom. 2010;11:724.CrossRef Johnson R, Nelson G, Troyer J, Lautenberger J, Kessing B, Wrinkler C, OBrien S. Accounting for multiple comparisons in a genome-wide association study (gwas). BMC Genom. 2010;11:724.CrossRef
35.
Zurück zum Zitat Kolossvary M, Karady J, Szilveszter B. Radiomic features are superior to conventional quantitative computed tomographic metrics to identify coronary plaques with napkin-ring sign. Circ Cardiovasc Imaging. 2017;12:10. Kolossvary M, Karady J, Szilveszter B. Radiomic features are superior to conventional quantitative computed tomographic metrics to identify coronary plaques with napkin-ring sign. Circ Cardiovasc Imaging. 2017;12:10.
36.
Zurück zum Zitat Orlhac F, Soussan M, Maisonobe J-A, Garcia C, Vanderlinden B, Buvat I. Tumor texture analysis in \(^{18}\)f-fdg pet: relationships between texture parameters, histogram indices, standardized uptake values, metabolic volumes, and total lesion glycolysis. J Nucl Med. 2014;55:414–22.PubMedCrossRef Orlhac F, Soussan M, Maisonobe J-A, Garcia C, Vanderlinden B, Buvat I. Tumor texture analysis in \(^{18}\)f-fdg pet: relationships between texture parameters, histogram indices, standardized uptake values, metabolic volumes, and total lesion glycolysis. J Nucl Med. 2014;55:414–22.PubMedCrossRef
37.
Zurück zum Zitat Perneger T. What’s wrong with bonferroni adjustments. Biomed J. 1998;316:1236. Perneger T. What’s wrong with bonferroni adjustments. Biomed J. 1998;316:1236.
38.
Zurück zum Zitat Bonferroni C. Teoria statistica delle classi e calcolo delle probabilita. Pubblicazioni dell Istituto Superiore di Scienze Economiche e Commerciali di Firenze. 1936;8:3–62. Bonferroni C. Teoria statistica delle classi e calcolo delle probabilita. Pubblicazioni dell Istituto Superiore di Scienze Economiche e Commerciali di Firenze. 1936;8:3–62.
39.
Zurück zum Zitat Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2015;278(2):563–77.PubMedCrossRef Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2015;278(2):563–77.PubMedCrossRef
40.
Zurück zum Zitat Kumar V, Gu Y, Basu S, Berglund A, Eschrich SA, Schabath MB, Forster K, Aerts HJ, Dekker A, Fenstermacher D, et al. Radiomics: the process and the challenges. Magn Reson Imaging. 2012;30(9):1234–48.PubMedPubMedCentralCrossRef Kumar V, Gu Y, Basu S, Berglund A, Eschrich SA, Schabath MB, Forster K, Aerts HJ, Dekker A, Fenstermacher D, et al. Radiomics: the process and the challenges. Magn Reson Imaging. 2012;30(9):1234–48.PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat Panth KM, Leijenaar RT, Carvalho S, Lieuwes NG, Yaromina A, Dubois L, Lambin P. Is there a causal relationship between genetic changes and radiomics-based image features? An in vivo preclinical experiment with doxycycline inducible gadd34 tumor cells. Radiother Oncol. 2015;116(3):462–6.PubMedCrossRef Panth KM, Leijenaar RT, Carvalho S, Lieuwes NG, Yaromina A, Dubois L, Lambin P. Is there a causal relationship between genetic changes and radiomics-based image features? An in vivo preclinical experiment with doxycycline inducible gadd34 tumor cells. Radiother Oncol. 2015;116(3):462–6.PubMedCrossRef
42.
Zurück zum Zitat Huang Y, Liu Z, He L, Chen X, Pan D, Ma Z, Liang C, Tian J, Liang C. Radiomics signature: a potential biomarker for the prediction of disease-free survival in early-stage (i or ii) non-small cell lung cancer. Radiology. 2016;281(3):947–57.PubMedCrossRef Huang Y, Liu Z, He L, Chen X, Pan D, Ma Z, Liang C, Tian J, Liang C. Radiomics signature: a potential biomarker for the prediction of disease-free survival in early-stage (i or ii) non-small cell lung cancer. Radiology. 2016;281(3):947–57.PubMedCrossRef
43.
Zurück zum Zitat Sørensen L, Igel C, Liv Hansen N, Osler M, Lauritzen M, Rostrup E, Nielsen M. Initiative, A.D.N., the Australian Imaging Biomarkers, of Ageing, L.F.S.: Early detection of alzheimer’s disease using m ri hippocampal texture. Hum Brain Mapp. 2016;37(3):1148–61.PubMedCrossRef Sørensen L, Igel C, Liv Hansen N, Osler M, Lauritzen M, Rostrup E, Nielsen M. Initiative, A.D.N., the Australian Imaging Biomarkers, of Ageing, L.F.S.: Early detection of alzheimer’s disease using m ri hippocampal texture. Hum Brain Mapp. 2016;37(3):1148–61.PubMedCrossRef
44.
Zurück zum Zitat Sørensen L, Igel C, Pai A, Balas I, Anker C, Lillholm M, Nielsen M, Initiative ADN, et al. Differential diagnosis of mild cognitive impairment and Alzheimer’s disease using structural mri cortical thickness, hippocampal shape, hippocampal texture, and volumetry. NeuroImage Clin. 2017;13:470–82.PubMedCrossRef Sørensen L, Igel C, Pai A, Balas I, Anker C, Lillholm M, Nielsen M, Initiative ADN, et al. Differential diagnosis of mild cognitive impairment and Alzheimer’s disease using structural mri cortical thickness, hippocampal shape, hippocampal texture, and volumetry. NeuroImage Clin. 2017;13:470–82.PubMedCrossRef
45.
Zurück zum Zitat Vidal CN, Nicolson R, DeVito TJ, Hayashi KM, Geaga JA, Drost DJ, Williamson PC, Rajakumar N, Sui Y, Dutton RA, et al. Mapping corpus callosum deficits in autism: an index of aberrant cortical connectivity. Biol Psychiatry. 2006;60(3):218–25.PubMedCrossRef Vidal CN, Nicolson R, DeVito TJ, Hayashi KM, Geaga JA, Drost DJ, Williamson PC, Rajakumar N, Sui Y, Dutton RA, et al. Mapping corpus callosum deficits in autism: an index of aberrant cortical connectivity. Biol Psychiatry. 2006;60(3):218–25.PubMedCrossRef
46.
Zurück zum Zitat Ferreira LK, Diniz BS, Forlenza OV, Busatto GF, Zanetti MV. Neurostructural predictors of Alzheimer’s disease: a meta-analysis of vbm studies. Neurobiol Aging. 2011;32(10):1733–41.PubMedCrossRef Ferreira LK, Diniz BS, Forlenza OV, Busatto GF, Zanetti MV. Neurostructural predictors of Alzheimer’s disease: a meta-analysis of vbm studies. Neurobiol Aging. 2011;32(10):1733–41.PubMedCrossRef
47.
Zurück zum Zitat Lerch JP, Pruessner J, Zijdenbos AP, Collins DL, Teipel SJ, Hampel H, Evans AC. Automated cortical thickness measurements from mri can accurately separate Alzheimer’s patients from normal elderly controls. Neurobiol Aging. 2008;29(1):23–30.PubMedCrossRef Lerch JP, Pruessner J, Zijdenbos AP, Collins DL, Teipel SJ, Hampel H, Evans AC. Automated cortical thickness measurements from mri can accurately separate Alzheimer’s patients from normal elderly controls. Neurobiol Aging. 2008;29(1):23–30.PubMedCrossRef
48.
Zurück zum Zitat Plant C, Teipel SJ, Oswald A, Böhm C, Meindl T, Mourao-Miranda J, Bokde AW, Hampel H, Ewers M. Automated detection of brain atrophy patterns based on mri for the prediction of Alzheimer’s disease. Neuroimage. 2010;50(1):162–74.PubMedCrossRef Plant C, Teipel SJ, Oswald A, Böhm C, Meindl T, Mourao-Miranda J, Bokde AW, Hampel H, Ewers M. Automated detection of brain atrophy patterns based on mri for the prediction of Alzheimer’s disease. Neuroimage. 2010;50(1):162–74.PubMedCrossRef
49.
Zurück zum Zitat Lerch JP, Evans AC. Cortical thickness analysis examined through power analysis and a population simulation. Neuroimage. 2005;24(1):163–73.PubMedCrossRef Lerch JP, Evans AC. Cortical thickness analysis examined through power analysis and a population simulation. Neuroimage. 2005;24(1):163–73.PubMedCrossRef
50.
Zurück zum Zitat Wee C-Y, Yap P-T, Shen D, Initiative ADN. Prediction of Alzheimer’s disease and mild cognitive impairment using cortical morphological patterns. Hum Brain Mapp. 2013;34(12):3411–25.PubMedCrossRef Wee C-Y, Yap P-T, Shen D, Initiative ADN. Prediction of Alzheimer’s disease and mild cognitive impairment using cortical morphological patterns. Hum Brain Mapp. 2013;34(12):3411–25.PubMedCrossRef
51.
Zurück zum Zitat Collins GS, Ogundimu DGEO. andAltman: sample size considerations for the external validation of a multivariable prognostic model: a resampling study. Stat Med. 2016;35:214–26.PubMedCrossRef Collins GS, Ogundimu DGEO. andAltman: sample size considerations for the external validation of a multivariable prognostic model: a resampling study. Stat Med. 2016;35:214–26.PubMedCrossRef
52.
Zurück zum Zitat Varma A, Snowden J, Lloyd J, Talbot P, Mann D, Neary D. Evaluation of the nincds-adrda criteria in the differentiation of Alzheimer’s disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry. 1999;66(2):184–8.PubMedPubMedCentralCrossRef Varma A, Snowden J, Lloyd J, Talbot P, Mann D, Neary D. Evaluation of the nincds-adrda criteria in the differentiation of Alzheimer’s disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry. 1999;66(2):184–8.PubMedPubMedCentralCrossRef
53.
Zurück zum Zitat Cho H, Seo SW, Kim J-H, Suh MK, Lee J-H, Choe YS, Lee K-H, Kim JS, Kim GH, Noh Y, et al. Amyloid deposition in early onset versus late onset Alzheimer’s disease. J Alzheimers Dis. 2013;35(4):813–21.PubMedCrossRef Cho H, Seo SW, Kim J-H, Suh MK, Lee J-H, Choe YS, Lee K-H, Kim JS, Kim GH, Noh Y, et al. Amyloid deposition in early onset versus late onset Alzheimer’s disease. J Alzheimers Dis. 2013;35(4):813–21.PubMedCrossRef
Metadaten
Titel
Correlation of [18F]florbetaben textural features and age of onset of Alzheimer’s disease: a principal components analysis approach
verfasst von
Jing Li
Emanuele Antonecchia
Marco Camerlenghi
Agostino Chiaravalloti
Qian Chu
Alfonso Di Costanzo
Zhen Li
Lin Wan
Xiangsong Zhang
Nicola D’Ascenzo
Orazio Schillaci
Qingguo Xie
Publikationsdatum
01.12.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
EJNMMI Research / Ausgabe 1/2021
Elektronische ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-021-00774-x

Weitere Artikel der Ausgabe 1/2021

EJNMMI Research 1/2021 Zur Ausgabe